Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Gabrielli

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Frontiers in Pharmacology|February 21, 2012
Defective cell cycle checkpoints as targets for anti-cancer therapiesBrian Gabrielli, Kelly Brooks, Sandra Pavey
Cancers|September 11, 2019
Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in CancerDeborah Nazareth, Mathew Jk Jones, Brian Gabrielli
Cell Cycle (Georgetown, Tex.)|May 22, 2004
Histone-deacetylase inhibitors for the treatment of cancerRalph K Lindemann, Brian Gabrielli, Ricky W Johnstone
The Journal of Biological Chemistry|August 31, 2010
Mitotic phosphorylation of Cdc25B Ser321 disrupts 14-3-3 binding to the high affinity Ser323 sitePuji Astuti, Rose Boutros, Bernard Ducommun, et al.
Annals of the New York Academy of Sciences|January 22, 2005
Defining the chemotherapeutic targets of histone deacetylase inhibitorsBrian Gabrielli, Robyn Warrener, Andrew Burgess, et al.
Molecular Pharmacology|June 12, 2010
The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activityKeeming Chia, Heather Beamish, Kaneez Jafferi, et al.
Pigment Cell & Melanoma Research|July 11, 2013
DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanomaSandra Pavey, Loredana Spoerri, Nikolas K Haass, et al.
Trends in Cell Biology|March 29, 2026
Tetraploids or polyploid giants: who is truly dangerous?Mathew Bloomfield, Shivam Vora, Dinethra Epa, et al.
Pigment Cell & Melanoma Research|October 1, 2018
Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomasNicholas D'Arcy, Nicholas Matigian, Kim-Anh Lê Cao, et al.
Molecular Pharmacology|June 22, 2010
Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylationRobyn Warrener, Keeming Chia, William D Warren, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Frontiers in Pharmacology|February 21, 2012
Defective cell cycle checkpoints as targets for anti-cancer therapiesBrian Gabrielli, Kelly Brooks, Sandra Pavey
Cancers|September 11, 2019
Everything in Moderation: Lessons Learned by Exploiting Moderate Replication Stress in CancerDeborah Nazareth, Mathew Jk Jones, Brian Gabrielli
Cell Cycle (Georgetown, Tex.)|May 22, 2004
Histone-deacetylase inhibitors for the treatment of cancerRalph K Lindemann, Brian Gabrielli, Ricky W Johnstone
The Journal of Biological Chemistry|August 31, 2010
Mitotic phosphorylation of Cdc25B Ser321 disrupts 14-3-3 binding to the high affinity Ser323 sitePuji Astuti, Rose Boutros, Bernard Ducommun, et al.
Annals of the New York Academy of Sciences|January 22, 2005
Defining the chemotherapeutic targets of histone deacetylase inhibitorsBrian Gabrielli, Robyn Warrener, Andrew Burgess, et al.
Molecular Pharmacology|June 12, 2010
The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activityKeeming Chia, Heather Beamish, Kaneez Jafferi, et al.
Pigment Cell & Melanoma Research|July 11, 2013
DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanomaSandra Pavey, Loredana Spoerri, Nikolas K Haass, et al.
Trends in Cell Biology|March 29, 2026
Tetraploids or polyploid giants: who is truly dangerous?Mathew Bloomfield, Shivam Vora, Dinethra Epa, et al.
Pigment Cell & Melanoma Research|October 1, 2018
Pathway dysregulation analysis of the nucleotide excision repair mechanisms reveals it is not a common feature of melanomasNicholas D'Arcy, Nicholas Matigian, Kim-Anh Lê Cao, et al.
Molecular Pharmacology|June 22, 2010
Inhibition of histone deacetylase 3 produces mitotic defects independent of alterations in histone H3 lysine 9 acetylation and methylationRobyn Warrener, Keeming Chia, William D Warren, et al.
Pageof 9